头孢哌酮/舒巴坦致神经外科患者凝血功能异常的特征及其风险因素

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (962 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the characteristics and risk factors of cefoperazone/sulbactam related coagulation dysfunction in neurosurgery patients. Methods A retrospective study was carried out on the neurosurgery patients treated with cefoperazone/sulbactam in the Neurosurgery Department of Xijing Hospital of Air Force Military Medical University from January 2020 to February 2023. The patients were divided into normal group and abnormal group according to whether there was coagulation dysfunction after medication. The risk prediction model was established based on relevant risk factors screened with LASSO regression. Results A total of 108 patients were involved, including 43 cases (39.81%) with abnormal coagulation dysfunction and 65 cases (60.19%) with normal coagulation function. Cefoperazone/sulbactam related coagulation dysfunction was characterized by prolonged PT and APTT, decreased PTA and increased INR. PT, PTA and INR were susceptible to cefoperazone/sulbactam and changed significantly, which could be used as sensitive indicators for risk identification. The risk of coagulation dysfunction after medication was positively correlated with APACHE Ⅱ score (OR=1.133, 95%CI: 1.039-1.234), age (OR=1.024, 95%CI: 0.993-1.054), and negatively correlated with PTA (OR=0.959, 95%CI: 0.929-0.989). Conclusions The use of nomogram for risk assessment to identify high-risk groups and strengthen the monitoring of PT, PTA, and APTT can reduce the occurrence of risk events.

Key words： cefoperazone/sulbactam coagulation dysfunction risk factors LASSO regression nomogram

Received: 02 January 2024

ZTFLH:

R969.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIN Xing
	LU Xiaoyun
	LI Yamei

Cite this article:

JIN Xing,LU Xiaoyun,LI Yamei. Characteristics and risk factors of cefoperazone/sulbactam related coagulation dysfunction in neurosurgery patients[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(6): 511-515.

URL:

https://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR https://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2024/V35/I6/511

[1]	Wang W, Liu Y, Yu C, et al. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study[J]. Expert Opin Drug Saf, 2020, 19(3): 339-347.
[2]	Song J C, Zhang W, Zhang Z, et al. Consensus of Chinese experts on standardized evaluation of coagulation dysfunction in severe patients[J]. Med J Chin PLA, 2022, 47(2): 107-117.
[3]	李艳艳, 时磊, 王延虹, 等. 头孢哌酮钠-舒巴坦钠致凝血功能异常的因素分析[J]. 中国合理用药探索, 2018, 15(11): 78-80.
[4]	梁河, 蒙光义, 钟丽球, 等. 头孢哌酮钠舒巴坦钠致缺血性脑血管病患者凝血功能异常的影响因素分析[J]. 中国药物警戒, 2022, 19(1): 87-90.
[5]	张寒钰, 吴迪, 王国兴, 等. 头孢哌酮/舒巴坦钠引起凝血功能异常的因素分析[J]. 中国病案, 2019, 20(6): 81-84.
[6]	Wong R, Cheng G, Chan N, et al. Use of cefoperazone still needs a caution for bleeding from induced vitamin K deficiency[J]. Am J Hematol, 2006, 81(1): 76-76.
[7]	陈文彬, 潘祥林. 诊断学[M]. 北京:人民卫生出版社, 2013: 291-292.
[8]	Heinze G, Wallisch C, Dunkler D. Variable selection-A review and recommendations for the practicing statistician[J]. Biometrical J, 2018, 60(3): 431-449.
[9]	庞立峰. 注射用头孢哌酮钠舒巴坦钠致凝血功能异常1例[J]. 中国药物警戒, 2018, 15(5): 312-313.
[10]	Wu S X, Wu G, Wu H B. A comparison of coagulation function in patients receiving aspirin and cefoperazone-sulbactam with and without vitamin K1: a retrospective, observational study[J]. Clin Ther, 2021, 43(12): e335-e345.
[11]	李颖, 胡永芳, 彭芳辰. 头孢哌酮/舒巴坦引起血小板减少症的循证分析[J]. 中国药学杂志, 2009, 44(24): 1938-1941.
[12]	郭晓明, 王莹, 刘娜, 等. 头孢哌酮钠舒巴坦钠致血小板减少症的危险因素分析[J]. 中国医院用药评价与分析, 2021, 21(10): 1273-1276.
[13]	Knaus W A, Draper E A, Wagner D P, et al. APACHE II: a severity of disease classification system[J]. Crit Care Med, 1985, 13(10): 818-829.
[14]	Retter A, Barrett N A. The management of abnormal haemostasis in the ICU[J]. Anaesthesia, 2015, 70 (Suppl. 1): 121-127.
[15]	Reitberg D P, Marble D A, Schultz R W, et al. Pharmacokinetics of cefoperazone (2.0g) and sulbactam (1.0g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis[J]. Antimicrob Agents Ch, 1988, 32(4): 503-509.
[16]	Singer M, Deutschman C S, Seymour C W, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 775-787.
[17]	Tsao C M, Ho S T, Wu C C. Coagulation abnormalities in sepsis[J]. Acta Anaesthesiol Taiwan, 2015, 53(1): 16-22.
[18]	黄业, 易文枫, 黄贵. 脓毒症患者凝血功能指标与预后的关系[J]. 临床医学研究与实践, 2020, 23: 115-116.